Back to top

AnaptysBio falls after data abstract on Lilly’s peresolimab

According to a report in the American College of Rheumatology, Eli Lilly’s (LLY) peresolimab was superior to the placebo at week 12 for several key...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

AnaptysBio, Inc. (ANAB)

Eli Lilly and Company (LLY)